7.48
+0.93(+14.20%)
Currency In USD
| Previous Close | 6.55 |
| Open | 6.44 |
| Day High | 7.7 |
| Day Low | 6.18 |
| 52-Week High | 17.4 |
| 52-Week Low | 5 |
| Volume | 44,233 |
| Average Volume | 140,046 |
| Market Cap | 9.43M |
| PE | -0.33 |
| EPS | -23 |
| Moving Average 50 Days | 7.08 |
| Moving Average 200 Days | 9.14 |
| Change | 0.93 |
If you invested $1000 in Sensei Biotherapeutics, Inc. (SNSE) since IPO date, it would be worth $19.79 as of June 20, 2025 at a share price of $7.48. Whereas If you bought $1000 worth of Sensei Biotherapeutics, Inc. (SNSE) shares 3 years ago, it would be worth $194.79 as of June 20, 2025 at a share price of $7.48.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Sensei Biotherapeutics Announces 1-for-20 Reverse Stock Split
GlobeNewswire Inc.
Jun 13, 2025 11:30 AM GMT
BOSTON, June 13, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that it will
Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress
GlobeNewswire Inc.
May 06, 2025 11:30 AM GMT
- Favorable clinical data in PD-(L)1 resistant patients - - Dose expansion enrollment complete with full data expected by year-end 2025 - - Cash runway into the second quarter of 2026 - BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutic
Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference
GlobeNewswire Inc.
Apr 02, 2025 11:30 AM GMT
BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that John C